June 2023
Volume 64, Issue 8
Open Access
ARVO Annual Meeting Abstract  |   June 2023
The Impact of Myopia on Regional Visual Field Loss and Progression in Glaucoma
Author Affiliations & Notes
  • Anagha Lokhande
    Harvard Ophthalmology AI Lab, Schepens Eye Research Institute of Massachusetts Eye and Ear, Harvard Medical School, Boston, Massachusetts, United States
    Brown University Warren Alpert Medical School, Providence, Rhode Island, United States
  • Yan Luo
    Harvard Ophthalmology AI Lab, Schepens Eye Research Institute of Massachusetts Eye and Ear, Harvard Medical School, Boston, Massachusetts, United States
  • Min Shi
    Harvard Ophthalmology AI Lab, Schepens Eye Research Institute of Massachusetts Eye and Ear, Harvard Medical School, Boston, Massachusetts, United States
  • Yu Tian
    Harvard Ophthalmology AI Lab, Schepens Eye Research Institute of Massachusetts Eye and Ear, Harvard Medical School, Boston, Massachusetts, United States
  • Tobias Elze
    Harvard Ophthalmology AI Lab, Schepens Eye Research Institute of Massachusetts Eye and Ear, Harvard Medical School, Boston, Massachusetts, United States
  • Louis R Pasquale
    Eye and Vision Research Institute, Icahn School of Medicine at Mount Sinai, New York, New York, United States
  • Lucy Q. Shen
    Massachusetts Eye and Ear, Harvard Medical School, Boston, Massachusetts, United States
  • Nazlee Zebardast
    Massachusetts Eye and Ear, Harvard Medical School, Boston, Massachusetts, United States
  • David S. Friedman
    Massachusetts Eye and Ear, Harvard Medical School, Boston, Massachusetts, United States
  • Michael Boland
    Massachusetts Eye and Ear, Harvard Medical School, Boston, Massachusetts, United States
  • Mengyu Wang
    Harvard Ophthalmology AI Lab, Schepens Eye Research Institute of Massachusetts Eye and Ear, Harvard Medical School, Boston, Massachusetts, United States
  • Footnotes
    Commercial Relationships   Anagha Lokhande None; Yan Luo None; Min Shi None; Yu Tian None; Tobias Elze Genentech, Code F (Financial Support); Louis Pasquale Eyenovia, Twenty/Twenty Therapeutics, Skye Biosciences, Code C (Consultant/Contractor); Lucy Shen Firecyte Therapeutics, Abbvie, Code C (Consultant/Contractor); Nazlee Zebardast None; David Friedman None; Michael Boland Carl Zeiss Meditec, Topcon, Code C (Consultant/Contractor); Mengyu Wang Genentech, Code F (Financial Support)
  • Footnotes
    Support  NIH R00 EY028631, Research To Prevent Blindness International Research Collaborators Award, Alcon Young Investigator Grant, NIH R21 EY030631, NIH R01 EY030575, NIH R01 EY015473, NIH R21 EY031725, NIH R01 EY033005 and NIH P30 EY003790
Investigative Ophthalmology & Visual Science June 2023, Vol.64, 1308. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Anagha Lokhande, Yan Luo, Min Shi, Yu Tian, Tobias Elze, Louis R Pasquale, Lucy Q. Shen, Nazlee Zebardast, David S. Friedman, Michael Boland, Mengyu Wang; The Impact of Myopia on Regional Visual Field Loss and Progression in Glaucoma. Invest. Ophthalmol. Vis. Sci. 2023;64(8):1308.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : To investigate the impact of myopia on regional visual field (VF) loss and VF progression in glaucoma.

Methods : Reliable SITA Standard 24-2 VFs were selected from a large academic institution. Cross-sectional linear regression analysis was performed to quantify the impact of myopia measured by spherical equivalent (SE) on regional VF loss. Associations for VF locations with p-values ≥ 0.05 were reset to zero for visualization. Logistic regression analysis was conducted by correlating SE with four different VF progression outcomes: (1) mean deviation (MD) progression: MD slope < 0 and p-value < 0.05; (2) VF index (VFI) progression: VFI slope < 0 and p-value < 0.05; (3) total deviation (TD) pointwise progression: at least three TD locations with TD slope ≤ -1 dB/year and p-value < 0.05; (4) MD fast progression: MD slope ≤ -1 dB/year and p-value < 0.05. All analyses were adjusted for patient demographics including age, sex, race, ethnicity, and language ability with additional adjustment baseline MD for progression prediction.

Results : The sample consisted of 55,321 eyes from 55,321 patients (mean MD: -5.2 ± 6.3 dB; mean SE: 0.4 ± 3.2 diopters; mean age: 57.2 ± 17.2 years; sex: female: 57.7%, male: 42.2% and unknown: 0.1%; race: White: 69.7%, Asian: 6.2%, African American: 10.7%, and other or unknown: 13.4%; ethnicity: Hispanic: 6.9%, non-Hispanic: 84.4%, and unknown: 8.7%; language ability: English speakers: 87.5%, Spanish speakers: 4.0%, other languages speakers: 4.7%, and unknown: 3.8%) and 8,037 patients with at least five reliable 24-2 VFs over four years for longitudinal analyses. Cross-sectional analysis revealed that more negative SE values were associated with more negative TD values in the paracentral VF region (Figure 1a). These results remained after MD adjustment (Figure 1b). Longitudinal analysis revealed that with MD adjustment, three of the four measures of VF progression had a higher likelihood of deterioration with more negative SE (Table 1): MD progression (odds ratio [OR] = 0.97, p = 0.008), VFI progression (OR = 0.97, p = 0.0001), and TD pointwise progression (OR = 0.97, p = 0.007). Similar results were seen without MD adjustment.

Conclusions : Eyes with myopia experience greater VF loss in the paracentral region. More severe baseline myopia in the context of glaucoma is associated with a higher likelihood of VF progression.

This abstract was presented at the 2023 ARVO Annual Meeting, held in New Orleans, LA, April 23-27, 2023.

 

 

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×